Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis.

Sun F, Ladha SS, Yang L, Liu Q, Shi SX, Su N, Bomprezzi R, Shi FD.

Muscle Nerve. 2014 Apr;49(4):487-94. doi: 10.1002/mus.23951. Epub 2014 Feb 27.

2.

Use and monitoring of low dose rituximab in myasthenia gravis.

Blum S, Gillis D, Brown H, Boyle R, Henderson R, Heyworth-Smith D, Hogan P, Kubler P, Lander C, Limberg N, Pillans P, Prain K, Staples C, Walsh M, McCombe P, Wong R.

J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):659-63. doi: 10.1136/jnnp.2010.220475. Epub 2010 Nov 11.

PMID:
21071753
3.

Rituximab therapy for Morvan syndrome associated with myasthenia gravis.

Weiss M.

Muscle Nerve. 2012 Jul;46(1):139-40. doi: 10.1002/mus.23311. No abstract available.

PMID:
22693003
4.

Rituximab for myasthenia gravis: three case reports and review of the literature.

Stieglbauer K, Topakian R, Schäffer V, Aichner FT.

J Neurol Sci. 2009 May 15;280(1-2):120-2. doi: 10.1016/j.jns.2009.02.357. Epub 2009 Mar 9. Review.

PMID:
19272616
5.

Rituximab for severe myasthenia gravis--experience from five patients.

Lindberg C, Bokarewa M.

Acta Neurol Scand. 2010 Oct;122(4):225-8. doi: 10.1111/j.1600-0404.2010.01345.x.

PMID:
20199513
6.

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, Jungbluth H, Robb S, Hilton-Jones D.

J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):671-3. doi: 10.1136/jnnp.2009.197632. Epub 2010 Apr 14.

PMID:
20392977
7.

Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.

Kuntzer T, Carota A, Novy J, Cavassini M, Du Pasquier RA.

Neurology. 2011 Feb 22;76(8):757-8. doi: 10.1212/WNL.0b013e31820d6290. No abstract available.

PMID:
21339503
8.

Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.

Stein B, Bird SJ.

J Clin Neuromuscul Dis. 2011 Mar;12(3):163-4. doi: 10.1097/CND.0b013e3181df2b3e. No abstract available.

PMID:
21321497
9.

Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.

Nelson RP Jr, Pascuzzi RM, Kessler K, Walsh LE, Faught PP, Ramanuja S, Pescovitz MD, Loehrer PJ Sr.

J Clin Neuromuscul Dis. 2009 Jun;10(4):170-7. doi: 10.1097/CND.0b013e31819a8403. Review.

PMID:
19494727
10.

Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Iorio R, Damato V, Alboini PE, Evoli A.

J Neurol. 2015 May;262(5):1115-9. doi: 10.1007/s00415-014-7532-3. Epub 2014 Oct 12. Review.

PMID:
25308632
11.

Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.

Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA.

Ann Rheum Dis. 2012 Nov;71(11):1881-7. doi: 10.1136/annrheumdis-2011-201189. Epub 2012 May 21.

PMID:
22615459
12.

[Proposal for rituximab treatment in patients with myasthenia gravis].

Konno S.

Rinsho Shinkeigaku. 2013;53(11):1312-4. Review. Japanese.

PMID:
24291971
13.

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.

Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT.

Muscle Nerve. 2013 Dec;48(6):992-3. doi: 10.1002/mus.24063. Epub 2013 Oct 7. No abstract available.

14.

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, Schlesier M, Voll RE, Thiel J.

PLoS One. 2012;7(5):e37626. doi: 10.1371/journal.pone.0037626. Epub 2012 May 21.

15.

Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis.

Catzola V, Battaglia A, Buzzonetti A, Fossati M, Scuderi F, Fattorossi A, Evoli A.

J Neurol. 2013 Aug;260(8):2163-5. doi: 10.1007/s00415-013-6987-y. Epub 2013 Jun 8. No abstract available.

PMID:
23749295
16.

Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.

Jovancevic B, Lindholm C, Pullerits R.

Lupus. 2013 Jun;22(7):664-74. doi: 10.1177/0961203313485489. Epub 2013 Apr 23. Review.

PMID:
23612795
17.

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.

Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y.

J Rheumatol. 2011 Apr;38(4):633-41. doi: 10.3899/jrheum.100729. Epub 2010 Dec 15.

PMID:
21159836
18.

Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study.

Collongues N, Casez O, Lacour A, Tranchant C, Vermersch P, de Seze J, Lebrun C.

Muscle Nerve. 2012 Nov;46(5):687-91. doi: 10.1002/mus.23412. Epub 2012 Aug 31.

PMID:
22941747
19.

Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.

Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, Juarez C, Gallardo E.

J Neuroimmunol. 2008 Sep 15;201-202:90-4. doi: 10.1016/j.jneuroim.2008.04.039. Epub 2008 Jul 23.

PMID:
18653247
20.

Rituximab in the management of refractory myasthenia gravis.

Zebardast N, Patwa HS, Novella SP, Goldstein JM.

Muscle Nerve. 2010 Mar;41(3):375-8. doi: 10.1002/mus.21521.

PMID:
19852027

Supplemental Content

Support Center